Edgar Filing: NEUROCRINE BIOSCIENCES INC - Form 4

NEUROCRINE Form 4 June 04, 2007	BIOSCIENC	CES INC									
FORM 4			CECU	DIFIE		GHANGI		-	PPROVAL		
	UNITED	STATES		RITIES . ashingtor			E COMMISSIO	N OMB Number:	3235-0287		
Check this boy if no longer subject to Section 16. Form 4 or	STATEM	CMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES							bires: January 31, 2005 imated average den hours per ponse 0.5		
Form 5 obligations may continue. See Instruction 1(b). Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940											
(Print or Type Respo	onses)										
1. Name and Address of Reporting Person <u>*</u> POPS RICHARD F			2. Issuer Name and Ticker or Trading Symbol NEUROCRINE BIOSCIENCES			-	5. Relationship of Reporting Person(s) to Issuer				
			INC [NBIX]				(Check all applicable)				
(Last) (First) (Middle) ALKERMES, INC., 88 SIDNEY STREET, 2ND FLR			3. Date of Earliest Transaction (Month/Day/Year) 06/01/2007			X Director 10% Owner Officer (give title Other (specify below) below)					
	4. If Amendment, Date Original Filed(Month/Day/Year)			 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting 							
CAMBRIDGE,	WIA 02139						Person				
(City)	(State)	(Zip)	Tab	ole I - Non-	Derivative	e Securities A	Acquired, Disposed	of, or Beneficia	lly Owned		
	ansaction Date nth/Day/Year)		Date, if	3. Transactio Code (Instr. 8)	4. Securi onAcquired Disposed (Instr. 3,	(A) or of (D)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
				Code V	Amount	(D) Price					
Reminder: Report of	n a separate line	e for each cla	ass of sec	urities bene	•	•					
					inforı requi	nation con red to resp ays a curre	spond to the colle tained in this forn ond unless the fo ently valid OMB co	n are not rm	SEC 1474 (9-02)		
	Tab					sposed of, or convertible	Beneficially Owned securities)	d			

1. Title of	2.	3. Transaction Date	3A. Deemed	4.	5. Number of	6. Date Exercisable and	7. Title and Amount of
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transacti	orDerivative	Expiration Date	Underlying Securities

Edgar Filing: NEUROCRINE BIOSCIENCES INC - Form 4

Security (Instr. 3)	or Exercise Price of Derivative Security		any (Month/Day/Year)	Code (Instr. 8)	Securities Acquired (A or Disposed (D) (Instr. 3, 4, and 5)	·	(ear)	(Instr. 3 and	4)
				Code V	(A) (I	D) Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (1)	\$ 12.37	06/01/2007		А	12,000	07/01/2007	06/01/2014	Common Stock	12,000

Reporting Owners

Reporting Owner Name / Address	ddress							
1.6	Director	10% Owner	Officer	Other				
POPS RICHARD F ALKERMES, INC. 88 SIDNEY STREET, 2ND FLR CAMBRIDGE, MA 02139	Х							
Signatures								
Margaret E. Valeur-Jensen, By Por Attorney	wer of	06/04/2007						
<u>**</u> Signature of Reporting Person			Date					

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) Represents option of which 1/12th of the shares underlying the option becomes vested and exercisable on July 1, 2007, an additional 1/12th of the shares underlying the option becomes vested and exercisable each month thereafter.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.